Evaluation of hepatic metabolic activity in non-alcoholic fatty livers on 18FDG PET/CT

Dostbil, Zeki; Varoglu, Erhan; Serdengeçti, Mustafa; Kaya, Buğra; Önder, Hakan; Sarı, Oktay

doi:10.1016/j.remn.2012.04.006

Cited by 9 publications

(9 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hernandez-Martinez et al reported that the FDG uptake was reduced in cirrhotic livers (defined by anatomical imaging criteria) compared to the control group [ 25 ]. Some studies, evaluating the 18 F-FDG uptake in liver steatosis, reported an increasing SUV compared to normal liver parenchyma, whereas others observed no such difference [ 26 – 28 ]. In addition, there is evidence that a higher hepatic glucose metabolism with higher 18 F-FDG uptake into the liver parenchyma is associated with increased expression of GLUT-1 and hexokinase II [ 29 , 30 ].…”

Section: Introductionmentioning

confidence: 99%

In vivo confirmation of altered hepatic glucose metabolism in patients with liver fibrosis/cirrhosis by 18F-FDG PET/CT

et al. 2018

View full text Add to dashboard Cite

ObjectiveThe aim of this study was to assess the value of 18F-FDG PET/CT for quantitative assessment of hepatic metabolism in patients with different stages of liver fibrosis/cirrhosis.Materials and methods18F-FDG PET/CT scans of 37 patients either with or without liver fibrosis/cirrhosis, classified according to the METAVIR score (F0-F4) obtained from histopathological analysis of liver specimen, were analyzed retrospectively and classified as follows: no liver fibrosis (F0, n = 6), mild liver fibrosis (F1, n = 11), advanced liver fibrosis (F2, n = 6), severe liver fibrosis (F3, n = 5), and liver cirrhosis (F4, n = 11). The liver-to-blood ratio (LBR, scan time corrected for a reference time of 75 min) was compared between patient groups.ResultsPatients with liver fibrosis or cirrhosis (≥ F1; LBR 1.53 ± 0.35) showed a significant higher LBR than patients with normal liver parenchyma (F0, 1.08 ± 0.23; P = 0.004). In direct comparison, LBR increased up to the advanced stage of liver fibrosis (F2; 2.00 ± 0.40) and decreased until liver cirrhosis is reached (F4, 1.32 ± 0.14).ConclusionFunctional changes in liver parenchyma during liver fibrosis/cirrhosis affect hepatic glucose metabolism and significantly differ between stages of liver fibrosis/cirrhosis, classified according to the METAVIR scoring system, as demonstrated by LBR quantification by 18F-FDG PET/CT.

show abstract

Section: Introductionmentioning

confidence: 99%

In vivo confirmation of altered hepatic glucose metabolism in patients with liver fibrosis/cirrhosis by 18F-FDG PET/CT

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Although patients in the fatty liver group in our study had higher serum enzyme levels, we could not detect any positive relation between SUVs and ALT and AST levels. It is known that BMI levels are higher in patients with fatty liver than in normal patients (13,21). In our study, we could not calculate BMI of patients since we did not get their height values, but mean body weight of the patients with hepatic steatosis were significantly higher.…”

Section: Discussionmentioning

confidence: 76%

“…Dostbil et al (13) assessed the relationship between fatty infiltration of liver and hepatic metabolic activity in 79 patients with hepatosteatosis on 18 FDG PET/CT. The control group in the study included 77 patients with a mean liver HU value greater than mean spleen HU value and the patient group included 79 patients in whom the mean liver HUvalue was lower than or equal to the mean spleen HU value.…”

Section: Discussionmentioning

confidence: 99%

“…Several studies have been conducted to investigate the possible effect of fatty infiltration on liver SUVs (8)(9)(10)(11)(12)(13)(14)(15). Some of these studies have reported no correlation between low attenuation due to high fat content of liver and 18 F-FDG uptake (10,13). In one study, FDG PET showed a significant negative correlation between the severity of fatty liver and SUVmax of the liver (15).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Assessment of the Effect of Fatty Infiltration on Hepatic FDG Uptake

Özülker¹,

Özülker²

2019

eamr

View full text Add to dashboard Cite

In fluorodeoxyglucose (FDG) positron emission tomography (PET)/computerized tomography (CT) studies, physiological liver FDG uptake has been used as a reference in the evaluation of FDG uptake in pathological processes, even in malignancies. There is an ongoing debate on the effect of liver attenuation and FDG uptake in the liver. We aimed to evaluate the possible effect of fatty infiltration on the standardized uptake value (SUV) of the liver. Methods: A total of 88 patients were included in this study. Subjects were divided into 2 groups by calculating the Hounsfield unit (HU) of the liver from the unenhanced CT part of the PET/CT study and comparing it with that of the spleen. Fatty liver group included 42 patients (26 female, 16 male) with a mean age of 59.6±11.6 years, while control group consisted of 46 patients (22 female, 24 male) with a mean age of 60.2±11 years. The patients with a mean liver attenuation value (in HU) equal and greater than that of spleen were enrolled in the control group, while the patients with a mean liver attenuation value lower than the spleen were included in the fatty liver group. A subset of patients in the fatty liver group with difference in attenuation between the liver and spleen of more than 10 HU (HUS-HUL >10) were evaluated separately. Age, weight, history of diabetes mellitus (DM) and chemotherapy, serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, simultaneous blood glucose levels during PET scan and the elapsed time between FDG injection and the beginning of PET scan were recorded. Results: The average SUVmean and SUVmax values were 2.7±0.7 and 3.6±0.9 in the fatty liver group, 2.8±0.7 and 3.8±1 in the HUS-HUL >10 group and 3.3±0.6 and 4.4±0.9 in the control group, respectively. The average SUVmean and SUVmax values of the fatty liver group and HUS-HUL >10 group were significantly different from the control group (p<0.05). The patients in the fatty liver group had higher ALT (p=0.025) and glucose levels (p=0.001), weight (p=0.001), and DM rate (p=0.002) compared to the control group. Conclusion: Hepatic steatosis causes a statistically significant decrease in SUVmean and SUVmax values in liver. Therefore, we must be careful when using the liver as an internal reference organ

show abstract

“…2 In this context, nuclear imaging techniques including SPECT and PET targeted with novel signaling pathways may show target-specific and biological characterization in viability and metabolic activity in the progression of NAFLD. 13…”

Section: Introductionmentioning

confidence: 99%

PET/SPECT Molecular Probes for the Diagnosis and Staging of Nonalcoholic Fatty Liver Disease

2019

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is a significant public health challenge afflicting approximately 1 billion individuals both in the Western world and in the East world. While liver biopsy is considered as gold standard in the diagnosis and staging of liver fibrosis, noninvasive imaging technologies, including ultrasonography, computed tomography, single-photon emission computed tomography (SPECT), magnetic resonance imaging, and positron emission tomography (PET) could offer more sensitive, comprehensive, and quantitative measurement for NAFLD. In this review, we focus on recent development and applications of PET/SPECT molecular probes that enable multispatial/temporal visualization and quantification of physiopathological progress at the molecular level in the NAFLD. We shall also discuss the limitations of current radioligands and future direction for PET/SPECT probe development.

show abstract

Evaluation of hepatic metabolic activity in non-alcoholic fatty livers on 18FDG PET/CT

Cited by 9 publications

References 30 publications

In vivo confirmation of altered hepatic glucose metabolism in patients with liver fibrosis/cirrhosis by 18F-FDG PET/CT

In vivo confirmation of altered hepatic glucose metabolism in patients with liver fibrosis/cirrhosis by 18F-FDG PET/CT

Assessment of the Effect of Fatty Infiltration on Hepatic FDG Uptake

PET/SPECT Molecular Probes for the Diagnosis and Staging of Nonalcoholic Fatty Liver Disease

Contact Info

Product

Resources

About